Eloralintide
Peptide therapy: benefits, side effects, cost and protocols
C201H319N49O65S2
Eloralintide is an investigational dual amylin and calcitonin receptor agonist being studied for weight management. It works by reducing appetite and slowing gastric emptying through amylin-pathway mechanisms that complement GLP-1-based therapies.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- FDA status
- Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
- Evidence
- Moderate Evidence
Mechanism
How Eloralintide works
Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling.
Evidence
Key studies
10 papers on PubMed / 7 human trials
- 01
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
- 02
Bhattachar S, Tham LS, Tidemann-Miller B et al
Diabetes Obes Metab / Diabetes Obes Metab / Phase 1
- 03
Eloralintide, a long-acting amylin agonist, shows proof of concept for obesity
- 04
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
- 05
Billings LK, Hsia S, Bays H et al
Lancet / Phase 2
- 06
Eloralintide demonstrates efficacy in obesity treatment in phase 2 randomized trial
- 07
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
- 08
Briere DA, Qu H, Lansu K et al
Mol Metab / Mol Metab
- 09
Eloralintide, a novel amylin receptor agonist, shows potential for obesity treatment
Compound
Eloralintide compound data
- Formula
- C201H319N49O65S2
- Mol. weight
- 4526 g/mol
- PubChem CID
- 175663130 ↗
- IUPAC
- 20-[[4-[[4-[[5-[[1-[2-[[2-[[4-amino-2-[[4-amino-2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[2-[[2-[[5-amino-2-[[2-[[2-[2-[[20-[(4-amino-4-carboxy-butanoyl)amino]-17-(2-amino-2-oxo-ethyl)-8,14-bis(1-hydroxyethyl)-11-methyl-7,10,13,16,19-pentaoxo-1,3-dithia-6,9,12,15,18-pentazacyclohenicosane-5-carbonyl]amino]propanoylamino]-3-hydroxy-butanoyl]amino]acetyl]amino]pentanoyl]amino]-4-methyl-pentanoyl]amino]propanoylamino]-4-carboxy-butanoyl]amino]-2-methyl-3-phenyl-propanoyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-butanoyl]amino]-5-guanidino-pentanoyl]amino]-3-hydroxy-propanoyl]amino]-3-hydroxy-propanoyl]amino]-4-oxo-butanoyl]-methyl-amino]-4-oxo-butanoyl]amino]-3-phenyl-propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-6-[[1-[2-[2-[[1-[[1-[[1-[[2-[[2-[[3-amino-1-[[1-[[2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]-3-oxo-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-2-methyl-propyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]-3-methyl-butyl]amino]-6-oxo-hexyl]amino]-1-carboxy-4-oxo-butyl]amino]-1-carboxy-4-oxo-butyl]amino]-20-oxo-icosanoic acid
FAQ
Eloralintide questions
What is ELORALINTIDE?
Eloralintide (LY3841136) is an investigational amylin receptor agonist being developed by Eli Lilly for weight management. It targets the amylin pathway, which is distinct from GLP-1 approaches.
How does ELORALINTIDE work?
Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling.
Is ELORALINTIDE legal to buy?
ELORALINTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy ELORALINTIDE?
ELORALINTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does ELORALINTIDE belong to?
ELORALINTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of ELORALINTIDE?
ELORALINTIDE has been studied for: Weight loss potential, Appetite regulation via amylin pathway, Novel mechanism of action. Eli Lilly investigational compound. Targets amylin pathway distinct from GLP-1.
News
Eloralintide in the news
Eloralintide: A selective alternative targeting the amylin receptor for obesity management - the-innovation.org
the-innovation.org / 5 months ago
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes - Eli Lilly
Eli Lilly / 1 month ago
New GLP-1 alternative, eloralintide, leads to 20% weight loss in trial - Medical News Today
Medical News Today / 12 months ago
Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agon - PR Newswire
PR Newswire / 4 months ago
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity - The Malaysian Reserve
The Malaysian Reserve / 26 days ago
News aggregated via Google News. Inclusion does not imply endorsement.
Considering Eloralintide?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.